Update on the dermatologic use of systemic glucocorticosteroids

Dermatol Ther. 2007 Jul-Aug;20(4):187-205. doi: 10.1111/j.1529-8019.2007.00133.x.

Abstract

Systemic glucocorticosteroids (GCS) remain a first-line therapy for a variety of dermatologic diseases. The purpose of this article is to review the major pharmacologic properties and drug interactions of GCS, as well as the mechanisms of action, dosing and delivery options, and major adverse effects. In addition, the present authors will discuss the major indications and practical suggestions for the use of systemic GCS in dermatology.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Interactions
  • Glucocorticoids / adverse effects
  • Glucocorticoids / pharmacology
  • Glucocorticoids / therapeutic use*
  • Humans
  • Hypothalamo-Hypophyseal System / drug effects
  • Osteonecrosis / chemically induced
  • Osteoporosis / chemically induced
  • Pituitary-Adrenal System / drug effects
  • Skin Diseases / drug therapy*

Substances

  • Glucocorticoids